Menu
Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that its Board of Directors is conducting a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its development assets and cash resources.
Update(s):
September 27, 2017: Alcobra Ltd. (ADHD) and Arcturus Therapeutics, Inc., a privately held biotechnology company developing novel RNA medicines, today announced the signing of a definitive agreement to merge the two companies in an all-stock transaction